期刊
CANCER CELL
卷 23, 期 2, 页码 139-141出版社
CELL PRESS
DOI: 10.1016/j.ccr.2013.01.018
关键词
-
资金
- NCI NIH HHS [T32 CA009172, R01 CA129974] Funding Source: Medline
ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据